William Blair Has Negative Forecast for Certara Q2 Earnings

Certara, Inc. (NASDAQ:CERT - Free Report) - Equities researchers at William Blair cut their Q2 2025 earnings per share (EPS) estimates for shares of Certara in a report issued on Tuesday, May 6th. William Blair analyst M. Smock now anticipates that the company will post earnings of $0.05 per share for the quarter, down from their previous forecast of $0.06. William Blair has a "Market Perform" rating on the stock. The consensus estimate for Certara's current full-year earnings is $0.28 per share.

Several other research firms also recently commented on CERT. Stephens restated an "overweight" rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. KeyCorp boosted their target price on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. TD Cowen initiated coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Robert W. Baird boosted their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Price Performance

CERT traded up $0.11 during midday trading on Thursday, reaching $11.98. 1,361,391 shares of the company's stock were exchanged, compared to its average volume of 1,290,656. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business has a 50-day simple moving average of $11.67 and a two-hundred day simple moving average of $11.67. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -59.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. Certara has a one year low of $8.64 and a one year high of $17.76.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The business had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara's revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Certara by 5.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 797,610 shares of the company's stock valued at $7,896,000 after acquiring an additional 40,218 shares during the period. Associated Banc Corp acquired a new stake in shares of Certara during the 1st quarter worth approximately $101,000. Maxi Investments CY Ltd bought a new stake in shares of Certara during the first quarter worth approximately $168,000. Geneva Capital Management LLC lifted its holdings in Certara by 3.9% in the first quarter. Geneva Capital Management LLC now owns 5,671,689 shares of the company's stock valued at $56,150,000 after buying an additional 213,089 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in Certara in the first quarter valued at approximately $950,000. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.